FindTrial
Sign In

MRI to check Response to chemotherapy in Breast cancer patients

Mid-cycle MRI to predict Complete Pathologic Response to Neoadjuvant chemotherapy in Breast cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/06/034325
Enrollment
40
Registered
2021-06-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Control Intervention1: NIL: NIL Control Intervention2: NIL: NIL

Sponsors

Dr Smiti Sripathi Research Award For Breast Imaging Endowment Fund
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with Early breast cancer being treated with Neoadjuvant chemotherapy. Patients diagnosed with Locally advanced breast cancer, being treated with Neoadjuvant chemotherapy. Baseline and mid-cycle MRI (taken after 3 cycles of chemotherapy) to be taken.

Exclusion criteria

Exclusion criteria: Patients with metastatic carcinoma of breast.

Design outcomes

Primary

MeasureTime frame
MRI study (DCE/DWI) of breast, taken Mid-cycle of Neoadjuvant chemotherapy, in Breast cancer patients, effectively helps predict complete pathological response after completion of NAC in Breast cancer patients. Timepoint: One and half year—

Secondary

MeasureTime frame
NILTimepoint: -—

Countries

India

Contacts

Public ContactDr Aantriksha Arunkumar Gupta

Manipal Academy of Higher Education

prakashini.k@manipal.edu9845053325

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026